Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬ £¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

Ò׼·å°ÐÏòEpCAMµÄCAR-TÁÆ·¨ÔÚÃÀ¹ú»ñÅúÁÙ´²

2024-02-23
|
»á¼ûÁ¿£º

΢ÐÅͼƬ_20240218154109_¸±±¾.jpg

Ò½ÏßÒ©ÎÅ

1. 2ÔÂ23ÈÕ£¬£¬£¬ £¬Ò׼·åÐû²¼Æä×ÔÖ÷Ñз¢µÄ°ÐÏòEpCAMµÄ×ÔÌåCAR-Tϸ°û×¢ÉäÒºIMC001µÄÁÙ´²ÊÔÑéÉêÇëÔÚÖйú¹ú¼ÒÒ©¼à¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©Åú×¼Ö®ºó£¬£¬£¬ £¬¿ËÈÕÓÖ»ñµÃÁËÃÀ¹úFDAµÄÁÙ´²Ñо¿ÔÊÐí£¬£¬£¬ £¬ÓÃÓÚÖÎÁÆEpCAM±í´ïÑôÐÔµÄÍíÆÚÏû»¯ÏµÍ³Ö×Áö£¬£¬£¬ £¬°üÀ¨µ«²»ÏÞÓÚÍíÆÚθ°©£¨GC£©/ʳ¹ÜθÁ¬Ïµ²¿ÏÙ°©£¨GEJ£©¡£¡£¡£¡£¡£¡£

2. 2ÔÂ23ÈÕ£¬£¬£¬ £¬ÎäÌTakeda£©ÖйúÐû²¼£¬£¬£¬ £¬Ïû»¯ÁìÓò²úÆ·ÈðΨÊ㣨ͨÓÃÃû£º×¢ÉäÓÃÌæ¶È¸ñ³ëÄ£©Õýʽ»ñµÃÖйú¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨NMPA£©Åú×¼£¬£¬£¬ £¬ÊÊÓÃÓÚÖÎÁƶ̳¦×ÛºÏÕ÷£¨SBS£©³ÉÈ˺Í1Ëê¼°ÒÔÉ϶ùͯ»¼Õß¡£¡£¡£¡£¡£¡£

3. 2ÔÂ22ÈÕ£¬£¬£¬ £¬ºãÈðÒ½Ò©Ðû²¼Æä×ÔÖ÷Ñз¢µÄCD79b°ÐÏò¿¹ÌåżÁªÒ©ÎADC£©×¢ÉäÓÃSHR-A1912»ñµÃÃÀ¹úFDAÊÚÓè¿ìËÙͨµÀ×ʸñ£¬£¬£¬ £¬ÄâÓÃÓÚÖÎÁƼÈÍù½ÓÊܹýÖÁÉÙ2ÏßÖÎÁƵĸ´·¢/ÄÑÖÎÐÔÃÖÂþ´óBϸ°ûÁܰÍÁö£¨R/R DLBCL£©¡£¡£¡£¡£¡£¡£

4. 2ÔÂ22ÈÕ£¬£¬£¬ £¬ÃâÒß·½ÖÛÐû²¼£¬£¬£¬ £¬Æä×ÔÖ÷Ñз¢µÄÕë¶ÔÖ×Áö΢ÇéÐεÄÃâÒß¼¤»î¼ÁIMB071703×¢ÉäÒºÕýʽ»ñµÃÃÀ¹úFDAÅú×¼¿ªÕ¹ÁÙ´²ÊÔÑé¡£¡£¡£¡£¡£¡£IMB071703ÊÇÒ»¿îCD40/ CD137£¨4-1BB£©ÖØ×éË«¹¦Ð§¿¹ÌåÈÚºÏÂѰ×£¬£¬£¬ £¬ÓÃÀ´¼¤»îÏÈÌìÃâÒߺÍ˳ӦÐÔÃâÒßµÄÓÐÓ÷´Ó¦¡£¡£¡£¡£¡£¡£

ͶÈÚÒ©ÊÂ

1. 2ÔÂ21ÈÕÐÂÎÅ£¬£¬£¬ £¬À¥ÇØÉúÎï˳ËìÍê³ÉÊýÍòÍòÔªÈÚ×Ê£¬£¬£¬ £¬Ëù»ñ×ʽð½«ÓÃÓڸù«Ë¾²úÆ·Ñз¢Í¶Èë¡¢²úÏßÔËÓª¼°Êг¡½á¹¹µÈ¡£¡£¡£¡£¡£¡£±¾ÂÖÈÚ×ÊÓÉÉÂÎ÷»ã¿ÆÁ¢ÒìͶ×ÊÓÐÏÞ¹«Ë¾£¨ÒÔϼò³ÆÉ´´Í¶£©¶À¼ÒͶ×Ê¡£¡£¡£¡£¡£¡£

¿Æ¼¼Ò©ÑÐ

1. ÔÚ¶¥¼â¿ÆÑÐÆÚ¿¯¡¶×ÔÈ»¡·ÔÓÖ¾Ëù½ÒÏþµÄÒ»ÏîÑо¿ÖУ¬£¬£¬ £¬À´×ÔÓ¢¹úÓë°ÂµØÀûµÄ¿ÆÑÐÍŶÓÕ¹ÏÖÁËÒ»ÖÖÁ¢ÒìµÄ°ÐÏòÂѰ׽µ½â£¨TPD£©·Ö×Ó£¬£¬£¬ £¬ÕâÀà±»³ÆÎª·Ö×ÓÄÚ¶þ¼Û½º£¨IBG£©µÄ·Ö×ÓÁ¬ÏµÁËÈÈÃÅÖÎÁÆÄ£Ê½ÂѰ׽µ½âǶºÏÌ壨PROTAC£©Óë·Ö×Ó½ºµÄÌØÕ÷£¬£¬£¬ £¬Äܹ»ÊµÏÖ¾ßµÍÆ¤Ä¦¶ûЧÁ¦µÄ½µ½â£¬£¬£¬ £¬ÓÐÍû¿ªÆôÐÂÒ»´úµÄTPDÖÎÁÆÄ£Ê½¡£¡£¡£¡£¡£¡£

[1]Hsia, O., Hinterndorfer, M., Cowan, A.D. et al. Targeted protein degradation via intramolecular bivalent glues. Nature (2024). https://doi.org/10.1038/s41586-024-07089-6

Ïà¹ØÐÂÎÅ
CAR-TÁÆ·¨Ç°Í¾´óºÃ£¬£¬£¬ £¬¿ÉÊÇÔõÑùʵÏÖÉÌÒµ»¯£¿£¿£¿£¿£¿
2015-11-03
CAR-TÊÇÏÖÔÚ×î¾ßÇ㸲ÐÔDZÁ¦µÄÐÂÐ˼¼ÊõÖ®Ò»£¬£¬£¬ £¬ÕâÖÖÃâÒßÁÆ·¨Í¨¹ýÌØÒìÐÔÐÞÊεÄTϸ°û¸ßЧʶ±ðÖ×Áöϸ°û£¬£¬£¬ £¬Ê¹µÃÔÚÖÎÁÆÖ×ÁöµÄͬʱ×èÖ¹Á˶ÔÕý³£×éÖ¯µÄËðÉË£¬£¬£¬ £¬ÒýÆðÁËÈ«ÇòµÄÆÕ±é¹Ø×¢¡£¡£¡£¡£¡£¡£
Ò׼·åÍê³ÉÈÚ×ʼÓËÙÍÆ½øCAR-TÁÆ·¨Ø­¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ
2023-01-02
12ÔÂ30ÈÕ£¬£¬£¬ £¬Ò׼·åÐû²¼Íê³ÉA+ÂÖ½üÁ½ÒÚÔªÈÚ×Ê¡£¡£¡£¡£¡£¡£±¾ÂÖͶ×ÊÓɹúͶ´´ÒµÁìͶ£¬£¬£¬ £¬¹úÉú×ÊÔ´µÈ¸úͶ£¬£¬£¬ £¬ÕÙļ×ʽðÖ÷ÒªÓÃÓÚ¼ÓËÙÍÆ½ø¸Ã¹«Ë¾ÆìÏÂIMC001¡¢IMC002¡¢IMC008µÈ¶à¸öCAR-T²úÆ·µÄÁÙ´²Ñо¿¡£¡£¡£¡£¡£¡£
CAR-TÁÆ·¨Ö÷ÒªÕë¶Ô°×Ѫ²¡Óë¶ñÐÔÁܰÍÁö£¬£¬£¬ £¬±¾Ñо¿Öй¹½¨Ä¬È»PD-1µÄshRNAÔØÌåÖÊÁ££¬£¬£¬ £¬²âÐòºóÖÊÁ£µÄÅжÏͨ¹ýÃÀ¸ß÷¾ÙÐÐ
2023-06-28
Chimeric antigen receptor T cells (CAR-T) immunotherapy has shown promising clinical results in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. The shRNA vector plasmid that silences PD-1 and preparation of CAR is constructed. The plasmids sequenced were fully identified by Medicilon.
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿